Opus Genetics IRD 深 滬
等待開盤 09-08 09:30:00 美东时间
4.67
+0.070
+1.52%
華盛通- 最 高4.80
- 今 開4.53
- 成交量 223.97万股
- 最 低 4.40
- 昨 收 4.60
- 總市值 3.89亿
- 52周最高 5.81
- 市盈率 靜 --
- 換手率 2.69%
- 52周最低 1.35
- 委 比 -57.73%
- 總股本 8319.58万
- 歷史最高 23.08
- 量 比 0.96
- 振 幅 8.70%
- 歷史最低 0.65
- 每 手 1
- 風險率 1.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | 云米科技狂飙逾83%，AI净水战略点燃市场；戴尔劲升近16%，AI服务器订单积压冲至950亿美元
云米科技狂飙逾83%，AI净水战略点燃市场；GoPro三日累升超180%，大股东入局+跨界AI光器件；戴尔劲升近16%，AI服务器订单积压达950亿美元>>
09-03 18:57
Opus Genetics Plans To Present Topline Clinical Data From Cohort 1 Of Its Phase 1/2 Study Of OPGx-BEST1 During Investor Conference Call And Webcast On September 9
Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ET Full clinical dataset and additional analyses evaluating key measures of visual function to be presented at upcoming medical meetings RES...
09-02 19:07
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
Longeveron Inc. appoints Nirav Jhaveri as Chief Financial Officer, bringing over 25 years of experience in biotech finance and capital markets. Jhaveri succeeds Marie Washburn, who returns to her role as Corporate Controller. The company highlights Jhaveri's expertise in advancing stem cell therapy, particularly its lead product laromestrocel, which is in Phase 2b trials for HLHS. Jhaveri aims to support the company's growth and operational effic...
08-19 20:05
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics, a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, announced that its Compensation Committee approved equity awards under the 2021 Inducement Plan for three non-executive employees. The awards, totaling 310,000 stock options, vest over four years and align with Nasdaq Listing Rule 5635(c)(4). The company focuses on gene therapies to restore vision and prevent blindness, with a pipel...
08-19 20:01
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9
RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and lowers the price target from $10 to $9.
08-08 04:00
Opus Genetics Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $755.000K Miss $2.470M Estimate
Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 16.67 percent decrease over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $755.000 thousand ...
08-06 19:29
TD Cowen Initiates Coverage On Opus Genetics with Buy Rating
TD Cowen analyst Ritu Baral initiates coverage on Opus Genetics (NASDAQ:IRD) with a Buy rating.
07-29 22:29
美股大行评级 | 高盛上调AMD目标价从450美元升至640美元；伯恩斯坦上调阿斯麦目标价从1971美元升至2623美元
今日重点评级关注：Roth Capital：维持Nuvectis Pharma"买入"评级，目标价从20美元升至33美元；摩根士丹利：维持GXO Logistics"超配"评级，目标价从75美元升至78美元
07-07 11:34
BTIG Reiterates Buy on Opus Genetics, Maintains $12 Price Target
BTIG analyst Thomas Shrader reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $12 price target.
07-07 00:54
